The Monkeypox Treatment Market is estimated to be valued at Us$ 82.86 Mn in 2023 and is expected to exhibit a CAGR Of 17 % over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

The monkeypox treatment market includes drugs and vaccines used for the treatment and prevention of monkeypox infection. The major products in the market are vaccines and antiviral drugs. Smallpox vaccines, such as ACAM2000 and JYNNEOS, provide protection against monkeypox. Tecovirimat, developed by SIGA Technologies Inc., is the first drug approved for the treatment of monkeypox.

Market Dynamics:

The monkeypox treatment market is driven by the rising prevalence of monkeypox cases globally. According to the World Health Organization (WHO), as of October 2022, over 77,000 confirmed cases of monkeypox have been reported from 110 countries globally. In addition, shortage of vaccines is also driving demand. For instance, in Europe and North America, demand has outpaced supply as more people seek protection against the rising risk. JYNNEOS is the only U.S approved monkeypox vaccine and there is currently limited supply to meet demand. Furthermore, increasing research and development activities for new vaccines and treatments are also promoting market growth. For example, Bavarian Nordic is developing an easy to administer 3rd generation monkeypox vaccine.

SWOT Analysis

Strength:
- increasing research and development in the field of monkeypox by key players such as SIGA Technologies Inc and Bavarian Nordic.
- growing awareness about monkeypox treatment options amongst common public as well as healthcare professionals.
- availability of smallpox vaccine which provides cross protection against monkeypox.

Weakness:
- limited availability of approved treatment options and vaccines for monkeypox currently.
- high cost of research and drug development process.

Opportunity:
- rising incidence of monkeypox cases globally presents huge market potential.
- funding support from government bodies for research on monkeypox drugs and vaccines.
- collaborations between research institutes and pharma companies can help expedite drug discovery.

Threats:
- threat from other infectious disease outbreaks diverting funds away from monkeypox research.
- stringent regulatory approvals for vaccines and therapeutics can delay market launch.

Key Takeaways

The Global Monkeypox Treatment Market Size is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing research investments from both private and public players.

Regional analysis

North America is currently the dominant region for monkeypox treatment market accounting for over 30% revenue share in 2023. This is attributed to rising cases of monkeypox infections in the US. Europe is anticipated to be the fastest growing regional market between 2023-2030 owing to rising R&D initiatives.

Key players

Key players operating in the monkeypox treatment market are SIGA Technologies Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA. and Emcure Pharma. SIGA Technologies Inc. leads the market with its oral smallpox antiviral drug TPOXX. Bavarian Nordic dominates the vaccine segment with JYNNEOS monkeypox/smallpox vaccine.

Read More  : http://insightsmarket.weebly.com/blog/the-monkeypox-treatment-market-is-estimated-to-witness-high-growth-owing-to-increased-research-and-development-activities